Cstone Pharmaceuticals Stock Performance
| CSPHF Stock | USD 0.89 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CStone Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, CStone Pharmaceuticals is likely to outperform the market. At this point, CStone Pharmaceuticals has a negative expected return of -0.17%. Please make sure to confirm CStone Pharmaceuticals' treynor ratio and rate of daily change , to decide if CStone Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CStone Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's technical indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 3 B | |
| Total Cashflows From Investing Activities | -826.6 M |
CStone |
CStone Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 100.00 in CStone Pharmaceuticals on September 29, 2025 and sell it today you would lose (11.00) from holding CStone Pharmaceuticals or give up 11.0% of portfolio value over 90 days. CStone Pharmaceuticals is currently producing negative expected returns and takes up 1.375% volatility of returns over 90 trading days. Put another way, 12% of traded pink sheets are less volatile than CStone, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CStone Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CStone Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CStone Pharmaceuticals, and traders can use it to determine the average amount a CStone Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.125
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSPHF |
Based on monthly moving average CStone Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CStone Pharmaceuticals by adding CStone Pharmaceuticals to a well-diversified portfolio.
CStone Pharmaceuticals Fundamentals Growth
CStone Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CStone Pharmaceuticals, and CStone Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CStone Pink Sheet performance.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.37 | |||
| Operating Margin | (3.42) % | |||
| Current Valuation | 539.57 M | |||
| Shares Outstanding | 1.19 B | |||
| Price To Book | 4.33 X | |||
| Price To Sales | 1.43 X | |||
| Revenue | 243.72 M | |||
| EBITDA | (1.9 B) | |||
| Cash And Equivalents | 1.36 B | |||
| Cash Per Share | 1.15 X | |||
| Total Debt | 115.81 M | |||
| Debt To Equity | 0.25 % | |||
| Book Value Per Share | 0.80 X | |||
| Cash Flow From Operations | (1.48 B) | |||
| Earnings Per Share | (0.25) X | |||
| Total Asset | 2.27 B | |||
About CStone Pharmaceuticals Performance
By analyzing CStone Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into CStone Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CStone Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CStone Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. The company was incorporated in 2015 and is headquartered in Shanghai, China. Cstone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 569 people.Things to note about CStone Pharmaceuticals performance evaluation
Checking the ongoing alerts about CStone Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CStone Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CStone Pharmaceuticals generated a negative expected return over the last 90 days | |
| CStone Pharmaceuticals has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 243.72 M. Net Loss for the year was (1.92 B) with profit before overhead, payroll, taxes, and interest of 136.89 M. | |
| CStone Pharmaceuticals has accumulated about 1.36 B in cash with (1.48 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 48.0% of the company shares are held by company insiders |
- Analyzing CStone Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CStone Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining CStone Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CStone Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CStone Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CStone Pharmaceuticals' pink sheet. These opinions can provide insight into CStone Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CStone Pink Sheet analysis
When running CStone Pharmaceuticals' price analysis, check to measure CStone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CStone Pharmaceuticals is operating at the current time. Most of CStone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CStone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CStone Pharmaceuticals' price. Additionally, you may evaluate how the addition of CStone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |